Thibert Michael J, Fordyce Christopher B, Cairns John A, Turgeon Ricky D, Mackay Martha, Lee Terry, Tocher Wendy, Singer Joel, Perry-Arnesen Michele, Wong Graham C
Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.
CJC Open. 2021 Feb 16;3(7):864-871. doi: 10.1016/j.cjco.2021.02.009. eCollection 2021 Jul.
Major bleeding (MB) is an independent predictor of mortality among ST-elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (pPCI). Prevention of access-site MB has received significant attention. However, limited data have been obtained on the influence of access-site MB vs non-access-site MB and association with subsequent adverse in-hospital outcomes in the STEMI population undergoing pPCI.
We identified 1494 STEMI patients who underwent pPCI between 2012 and 2018. Unadjusted and adjusted differences among patients with no MB, access-site MB, non-access-site MB, and in-hospital clinical outcomes were assessed. The use of bleeding-avoidance strategies and their effects on MB were also evaluated.
MB occurred in 121 (8.1%) patients. Access-site MB occurred in 34 (2.3%) patients, and non-access-site MB occurred in 87 (5.8%). The median reduction in hemoglobin was 31 g/L (interquartile range: 19-43) with access-site MB, and 44 g/L (interquartile range: 29-62) with non-access-site MB. After multivariable adjustment, non-access-site MB was independently associated with in-hospital death (adjusted odds ratio [aOR] 4.21; 95% confidence interval [CI] 2.04-8.68), cardiogenic shock (aOR 10.91; 95% CI 5.67-20.98), and cardiac arrest (aOR 5.63; 95% CI 2.88-11.01). Conversely, access-site MB was not associated with adverse in-hospital outcomes. Bleeding-avoidance strategies were used frequently; however, after multivariable adjustment, no single bleeding-avoidance strategy was significantly associated with reduced MB.
In STEMI patients undergoing pPCI, non-access-site MB was independently associated with adverse in-hospital outcomes, whereas access-site MB was not. Additional study of strategies to reduce the incidence and impact of non-access-site MB appears to be warranted.
大出血(MB)是接受直接经皮冠状动脉介入治疗(pPCI)的ST段抬高型心肌梗死(STEMI)患者死亡率的独立预测因素。穿刺部位大出血的预防受到了广泛关注。然而,关于穿刺部位大出血与非穿刺部位大出血的影响以及与接受pPCI的STEMI患者随后住院不良结局的关联,所获数据有限。
我们确定了2012年至2018年间接受pPCI的1494例STEMI患者。评估了无大出血、穿刺部位大出血、非穿刺部位大出血患者之间未经调整和调整后的差异以及住院临床结局。还评估了避免出血策略的使用及其对大出血的影响。
121例(8.1%)患者发生大出血。穿刺部位大出血发生在34例(2.3%)患者中,非穿刺部位大出血发生在87例(5.8%)患者中。穿刺部位大出血患者血红蛋白的中位降低值为31 g/L(四分位间距:19 - 43),非穿刺部位大出血患者为44 g/L(四分位间距:29 - 62)。经过多变量调整后,非穿刺部位大出血与住院死亡(调整后的优势比[aOR] 4.21;95%置信区间[CI] 2.04 - 8.68)、心源性休克(aOR 10.91;95% CI 5.67 - 20.98)和心脏骤停(aOR 5.63;95% CI 2.88 - 11.01)独立相关。相反,穿刺部位大出血与住院不良结局无关。经常使用避免出血策略;然而,经过多变量调整后,没有单一的避免出血策略与大出血减少显著相关。
在接受pPCI的STEMI患者中,非穿刺部位大出血与住院不良结局独立相关,而穿刺部位大出血则不然。似乎有必要进一步研究降低非穿刺部位大出血发生率及其影响的策略。